author-photo

Yaron Pereg

19

Papers

150

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.

2020 Cancer
Show All
- Source
- Cite
- Save
Citations (4)
Results of a Non-Interventional Clinical Trial of Apograft — a Novel Technology for GvHD Prevention

2017 Blood
Show All
- Source
- Cite
- Save
Citations (0)
CXCR4 promotes neuroblastoma growth and therapeutic resistance through miR-15a/16-1 mediated ERK and BCL2/cyclin D1 pathways

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (24)
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression

2017 Leukemia
Show All
- Source
- Cite
- Save
Citations (57)
Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (28)
The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

2016 Blood
Show All
- Source
- Cite
- Save
Citations (5)
The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression

2016 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients

2016 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

2015 Blood
Show All
- Source
- Cite
- Save
Citations (14)
BL-8040, a CXCR4 antagonist, synergizes with the FLT3 inhibitor AC220 inducing apoptosis and reducing minimal residual disease to prolong survival of AML diseased mice

2015 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)